IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

GUNARATNAM Atty. Ref.: 4398-336

Serial No. New Application TC/A.U.: Unassigned

Filed: April 9, 2004 Examiner: Unassigned

For: A MASK WITH INTEGRAL CUSHION AND FOREHEAD PIECE

* * * * * * * * * * *

April 9, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Listed on accompanying Form PTO-1449 is information that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. At least one of the boxes below applies to the present application:

- 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required.
 - a. Contingent Request to Treat Under 37 C.F.R. § 1.97(c)

 In the event a first Office Action has been mailed prior to filing of the present Information Disclosure Statement and the Office Action was mailed more than three months since the filing of the application (for regular applications not including CPAs or RCEs), the Office is requested to treat the present paper as a submission under 37 C.F.R. § 1.97(c) and charge the

undersigned's Deposit Account No. 14-1140 for the fee required by 37 C.F.R. § 1.17(p). The present paper is submitted in duplicate for this purpose.

- b. Contingent Request to Treat Under 37 C.F.R. § 1.97(e)(1)
 In the event a first Office Action has been mailed prior to the filing of the present Information Disclosure Statement, and the Office Action was mailed more than three months since the filing of the application (for regular applications not including CPAs or RCEs), the Office is requested to treat the present paper as a submission under 37 C.F.R. § 1.97(e)(1) in that the undersigned hereby states that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
- c. Contingent Request to Treat Under 37 C.F.R. § 1.97(e)(2)

 In the event a first Office Action has been mailed prior to the filing of the present Information Disclosure Statement, and the Office Action was mailed more than three months since the filing of the application (for regular applications not including CPAs or RCEs), the Office is requested to treat the present paper as a submission under 37 C.F.R. § 1.97(e)(2) in that the undersigned hereby states that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

2.	☐ This Information Disclosure Statement is being filed more than three	
months after	the U.S. filing date AND after the mailing date of the first Office Action on	
the merits, but before the mailing date of a Final Rejection or Notice of Allowance.		
	a.	
	Information Disclosure Statement was first cited in any communication	
	from a foreign patent office in a counterpart foreign application not more	
	than three months prior to the filing of this Information Disclosure	
	Statement. 37 C.F.R. § 1.97(e)(1). Contingent Request Under 37 C.F.R. §	
	1.97(d). In the event a Notice of Allowance or a Final Rejection has been	
	mailed prior to filing this Information Disclosure Statement, the Office is	
	authorized to treat this as a submission under 37 C.F.R. 1.97(d) and charge	
	the undersigned's Deposit Account No. 14-1140 for the fee required by 37	
	C.F.R. § 1.17(p). The present paper is submitted in duplicate for this	
	purpose.	
	b.	
	Disclosure Statement was cited in a communication from a foreign patent	
	office in a counterpart foreign application, and, to my knowledge after	
	making reasonable inquiry, no item of information contained in this	
	Information Disclosure Statement was known to any individual designated	
	in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this	
	Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).	
	c. Attached is our check in the amount of \$ in payment of	
	the fee under 37 C.F.R. § 1.17(p).	
3.	☐ This Information Disclosure Statement is being filed more than three	
months after	the U.S. filing date and after the mailing date of a Final Rejection or Notice	
of Allowance, but before payment of the Issue Fee 37 C.F.R. § 1.97(d). It is hereby		
requested that the Information Disclosure Statement be considered. Attached is our		
check in the amount of \$\\$ in payment of the fee under 37 C.F.R. \§ 1.17(i).		
	a.	
	Information Disclosure Statement was first cited in any communication	

	from a foreign patent office in a counterpart foreign application not more
	than three months prior to the filing of this Information Disclosure
	Statement. 37 C.F.R. § 1.97(e)(1).
	b.
	Disclosure Statement was cited in a communication from a foreign patent
	office in a counterpart foreign application, and, to my knowledge after
	making reasonable inquiry, no item of information contained in this
	Information Disclosure Statement was known to any individual designated
	in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this
	Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
4.	Relevance of the non-English language document(s) is discussed in the
present speci	fication.
5.	The document(s) was/were cited in a corresponding foreign application
An English la	anguage version of the foreign search report or official action is attached for
the Examine	r's information. See MPEP § 609.
	a. U.S. Patent No. is indicated in the foreign search report or
	Official Action as being in the same patent family and/or the English-
	language equivalent of listed on the attached foreign search report.
6.	A concise explanation of the relevance of the non-English language
document(s)	appears below:
7.	Copies of the documents were cited by or submitted to the Office in
Application l	No. , filed , which is relied upon for an earlier filing date under
35 U.S.C. § 1	120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).
8.	The publication date (e.g., month or year) of at least one of the listed
documents is	not available. For each document in this category, the Office is requested
to assume that	at the year of publication of each listed document is earlier than the effective
U.S. filing da	ate and/or any foreign priority date.
9.	☐ The publication date of at least one document is listed on the attached
PTO-1449 ba	ased on information presently available to the undersigned. However, each
listed publics	ation date should not be construed as an admission that the information was

GUNARATNAM Serial No. New Application

actually published on the date indicated, and the right to challenge each listed publication date is expressly reserved by Applicant(s).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 14-1140 referencing docket number 4398-336.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

Paul T. Bowen Reg. No. 38,009

PTB:jck

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714

Telephone: (703) 816-4000 Facsimile: (703) 816-4100

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date Considered

The ultimate interface for CPAP treatment", 4 pages (no date).

/Steven Douglas/

*Examiner

08/09/2007